Sanofi, Cipla collaborate to expand Central Nervous System portfolio reach in India
Mumbai: Sanofi India Limited and Sanofi Healthcare India Private Limited, and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India.
As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category.
"While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them," the release stated.
Rodolfo Hrosz,Managing Director, Sanofi India Limited said, “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”
Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited said, “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”
Established in 1935, Cipla is a global pharmaceutical company. The Company is focused on deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. Cipla's strengths are in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Its 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products to cater to 80+ markets.
